6.1 The committee concluded that there is good evidence to support the clinical benefit of longer battery life and the associated reduction in cardiac resynchronisation therapy-defibrillator (CRT‑D) replacements.
6.2 The committee concluded that developments in CRT‑D technology are ongoing and that the evidence available suggests that the advantages of longer battery life have not been surpassed by other types of technical advances.
6.3 The committee noted the potential hazards of a clinical service relying solely on a single manufacturer's CRT‑D devices.
6.4 The committee encouraged further studies that provide data on the battery life of different CRT‑Ds, including an analysis of currently available UK NHS clinical data.
6.5 Based on cost modelling, the committee concluded that using ENDURALIFE‑powered CRT‑Ds in patients with heart failure is likely to save costs by reducing the number of replacement procedures.